What are the ACR guidelines for the use of febuxostat ULT in gout?

Updated: Jan 26, 2021
  • Author: Bruce M Rothschild, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print
Answer

Febuxostat:

  • Switching to an alternative oral ULT agent, if available and consistent with other recommendations in this guideline, is conditionally recommended for patients taking febuxostat with a history of cardiovascular disease (CVD) or a new CVD-related event.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!